October 28, 2022. The Court in the Innocoll securities matter (Eastern District of Pennsylvania) approved a class action settlement in the amount of $2.755 million. Plaintiff alleged that defendants concealed risks relating to the likelihood that the company’s pain management drug XaraColl would receive FDA approval. Plaintiffs retained Crowninshield Financial Research to provide expert analysis and consult on the computation of damages.


Additional information is available at Bloomberg Law News.